Eiko Lifesciences Ltd
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
- Market Cap ₹ 73.0 Cr.
- Current Price ₹ 58.6
- High / Low ₹ 81.3 / 45.1
- Stock P/E 65.8
- Book Value ₹ 41.2
- Dividend Yield 0.00 %
- ROCE 2.82 %
- ROE 1.87 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 24.4%
- Company has a low return on equity of 2.44% over last 3 years.
- Company has high debtors of 172 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.12 | 0.10 | 0.11 | 0.58 | 0.40 | 0.51 | 0.39 | 0.00 | 11.99 | 25.41 | 18.32 | 27.93 | 33.50 | |
0.12 | 0.09 | 0.08 | 0.47 | 0.14 | 0.18 | 0.20 | 0.17 | 11.47 | 24.10 | 17.35 | 26.32 | 31.77 | |
Operating Profit | 0.00 | 0.01 | 0.03 | 0.11 | 0.26 | 0.33 | 0.19 | -0.17 | 0.52 | 1.31 | 0.97 | 1.61 | 1.73 |
OPM % | 0.00% | 10.00% | 27.27% | 18.97% | 65.00% | 64.71% | 48.72% | 4.34% | 5.16% | 5.29% | 5.76% | 5.16% | |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.46 | 0.67 | 0.85 | 0.18 | 0.51 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.05 | 0.03 | 0.07 | 0.09 | 0.48 | 0.16 | 0.15 | 0.12 |
Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.06 | 0.06 | 0.06 | 0.56 | 0.63 | 0.66 | 0.67 |
Profit before tax | 0.00 | 0.01 | 0.03 | 0.11 | 0.22 | 0.22 | 0.10 | 0.13 | 0.83 | 0.94 | 1.03 | 0.99 | 1.45 |
Tax % | 0.00% | 33.33% | 27.27% | 27.27% | 13.64% | 30.00% | 0.00% | 26.51% | 24.47% | 25.24% | 23.23% | ||
0.00 | 0.01 | 0.02 | 0.08 | 0.17 | 0.18 | 0.07 | 0.13 | 0.61 | 0.71 | 0.77 | 0.75 | 1.11 | |
EPS in Rs | 0.00 | 0.33 | 0.04 | 0.16 | 0.34 | 0.28 | 0.11 | 0.20 | 0.95 | 0.51 | 0.55 | 0.64 | 0.89 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 44.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 76% |
5 Years: | 135% |
3 Years: | 33% |
TTM: | 40% |
Compounded Profit Growth | |
---|---|
10 Years: | 54% |
5 Years: | 61% |
3 Years: | 7% |
TTM: | 52% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 33% |
3 Years: | -4% |
1 Year: | -5% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 3% |
3 Years: | 2% |
Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.20 | 0.20 | 3.02 | 3.02 | 3.02 | 3.82 | 3.82 | 3.82 | 3.82 | 8.32 | 8.32 | 12.87 | 12.87 |
Reserves | -0.01 | 0.00 | 0.02 | 0.10 | 0.21 | 1.73 | 1.61 | 1.66 | 8.71 | 20.31 | 21.11 | 37.81 | 38.36 |
0.00 | 0.02 | 0.00 | 0.25 | 0.41 | 0.37 | 0.31 | 0.26 | 1.83 | 4.63 | 0.05 | 0.00 | 0.43 | |
0.00 | 0.00 | 0.01 | 0.02 | 0.12 | 0.06 | 0.02 | 0.02 | 2.25 | 1.64 | 1.57 | 2.06 | 3.12 | |
Total Liabilities | 0.19 | 0.22 | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 54.78 |
0.00 | 0.00 | 0.00 | 0.00 | 0.49 | 0.43 | 0.37 | 0.31 | 0.25 | 14.29 | 13.88 | 13.57 | 13.08 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.16 | 0.16 | 0.26 | 2.59 | 2.45 | 3.58 | 2.13 | 0.50 | 0.22 | 0.20 | 0.05 | 4.02 | 10.48 |
0.03 | 0.06 | 2.79 | 0.80 | 0.82 | 1.97 | 3.26 | 4.95 | 16.14 | 20.41 | 17.12 | 35.15 | 31.22 | |
Total Assets | 0.19 | 0.22 | 3.05 | 3.39 | 3.76 | 5.98 | 5.76 | 5.76 | 16.61 | 34.90 | 31.05 | 52.74 | 54.78 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.14 | -0.01 | -0.05 | 0.19 | 0.19 | 0.24 | -0.19 | 0.77 | -0.83 | -7.73 | 4.22 | -7.08 | |
-0.16 | 0.00 | -2.75 | 0.05 | -0.38 | -1.33 | -0.43 | -0.65 | -2.94 | 0.59 | 0.87 | -0.55 | |
0.02 | 0.01 | 2.80 | 0.25 | 0.15 | 1.82 | -0.08 | -0.13 | 7.81 | 3.28 | -4.70 | 20.36 | |
Net Cash Flow | 0.00 | 0.00 | 0.01 | 0.49 | -0.04 | 0.72 | -0.71 | -0.01 | 4.05 | -3.85 | 0.40 | 12.73 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 30.42 | 109.50 | 331.82 | 0.00 | 0.00 | 0.00 | 74.87 | 103.81 | 65.50 | 141.66 | 171.59 | |
Inventory Days | 0.00 | 2.06 | 88.26 | 20.64 | 48.70 | |||||||
Days Payable | 65.30 | 21.82 | 23.82 | 19.82 | ||||||||
Cash Conversion Cycle | 30.42 | 109.50 | 331.82 | 0.00 | 0.00 | 0.00 | 74.87 | 40.57 | 131.94 | 138.48 | 200.46 | |
Working Capital Days | 30.42 | 109.50 | 298.64 | 169.91 | 127.75 | 200.39 | 561.54 | 133.34 | 153.84 | 149.23 | 210.14 | |
ROCE % | 0.00% | 4.88% | 1.84% | 3.43% | 6.85% | 5.65% | 2.23% | 3.48% | 9.15% | 5.88% | 3.70% | 2.82% |
Documents
Announcements
-
Revised Outcome Of Right Issue Committee Meeting
1d - Approval of Final Reminder Cum Forfeiture Notice for shareholders.
-
Outcome Of The Meeting Of The Right Issue Committee Of Board Of Director Held On 25Th September, 2024
1d - Approval of Final Reminder Cum Forfeiture Notice.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
1d - Lenus Finvest acquired 9,52,385 shares of Eiko Lifesciences.
-
Board Meeting Intimation for Discussion On Final Reminder And Forfeiture Of The Partly Paid-Up Equity Shares On Which Call Money Has Not Been Received By The Company.
19 Nov - Meeting to discuss forfeiture of partly paid-up shares.
-
Post-Offer Public Announcement
12 Nov - Lenus Finvest announces open offer for Eiko Lifesciences.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
ELL is in the business of manufacturing, processing, formulating, producing, buying, selling, and exporting specialty and Fine Chemicals comprising organic & inorganic chemicals, and Pharma Intermediates, etc.